A pill that makes pancreatic cancer disappear? What the daraxonrasib trial found
A groundbreaking trial has shown that an experimental pill, daraxonrasib, may significantly impact the treatment of advanced pancreatic cancer, a disease with a notoriously low survival rate. Among 61 patients with metastatic pancreatic cancer, the drug halted tumor growth in 90% of participants, while tumor size decreased or vanished in over half of the patients.
In nearly 8% of cases, tumors were completely undetectable on CT scans. Notably, 76.6% of participants remained alive a year after beginning treatment, compared to an average of 40-45% survival among patients receiving chemotherapy alone.
Dr. Parveen Jain, Senior Consultant and Head of Medical Oncology at Aakash Healthcare, explained that daraxonrasib targets the KRAS gene, which is commonly altered in pancreatic cancer. KRAS sends continuous signals that promote cancer cell growth and survival. By blocking these faulty signals, daraxonrasib disrupts the molecular pathways sustaining tumor growth.
Unlike conventional chemotherapy, which targets rapidly dividing cells, including some healthy ones, targeted therapies like daraxonrasib aim to block specific molecular pathways unique to cancer cells.
However, targeted treatment also poses challenges, such as potential side effects and the possibility of cancer cells developing resistance. While an undetectable tumor on a CT scan is a positive sign, it does not guarantee a cure. Cancer cells may remain hidden and eventually proliferate, leading to cancer recurrence. Dr. Jain emphasized that long-term follow-up studies are crucial to determine whether these responses are sustained and if the treatment can lead to durable remission.
The trial's one-year survival rate of 76.6% is promising compared to historical survival figures for patients receiving chemotherapy alone. However, Dr. Jain cautioned against interpreting this as definitive evidence that daraxonrasib improves survival. The study involved a small sample size of 61 patients and used a historical comparison to chemotherapy rather than a randomized group.
Future trials are necessary to ascertain whether the treatment improves overall survival or progression-free survival compared to standard chemotherapy. Long-term safety, treatment resistance, quality of life, and the patient groups most likely to benefit from daraxonrasib will also require assessment.
While these findings offer hope, Dr. Jain stressed that more evidence is needed before daraxonrasib can be considered a standard treatment for pancreatic cancer.
Rewritten by urgent.news; may contain errors — check the original.
This story
This is one outlet's version. Read the fullest account.
- Massive hope for pancreatic cancer pill after trial saw tumours vanish gbcghanaonline.com
- A pill that makes pancreatic cancer disappear? What the daraxonrasib trial found indianexpress.com
- Massive hope for pancreatic cancer pill after trial saw tumours vanish myjoyonline.com
- Massive hope for pancreatic cancer pill after trial saw tumours vanish bbc.co.uk